NCT04173403View on ClinicalTrials.gov

A Long-term Study of AK102 in Patients With Hypercholesterolemia

PHASE2CompletedINTERVENTIONAL
Enrollment

796

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

February 17, 2023

Study Completion Date

February 17, 2023

Conditions
Hypercholesterolemia
Interventions
DRUG

450mg AK102

AK102 Q4W

DRUG

300mg AK102

AK102 Q4W

DRUG

150mg AK102

AK102 Q2W

DRUG

Statins and/or Ezetimibe

Lipid-lowering therapies

Trial Locations (1)

100000

Peking Union Medical College Hospital, Beijing

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
collaborator

AD Pharma (Guangdong)

UNKNOWN

lead

Akeso

INDUSTRY